Light therapy and donor cells aim to stop kidney rejection
NCT ID NCT07083830
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This early-stage trial tests whether giving kidney transplant recipients a special treatment made from their donor's cells, combined with a light-based therapy called photopheresis, can safely reduce the risk of organ rejection. About 24 adults receiving their first kidney transplant will take part. The main goal is to check safety and see if this approach lowers rejection rates compared to past patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- Can a vaccine shield transplant patients from shingles?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- Can a single drug dose forecast transplant kidney health?